Effects of lauric acid on upper gut motility, plasma cholecystokinin and peptide YY, and energy intake are load, but not concentration, dependent in humans

What Was Tested

The paper reports a study of Peptide YY and Cholecystokinin (CCK), published as a randomized controlled trial.

The researchers postulated that, in humans, the modulation of antropyloroduodenal pressure waves, plasma cholecystokinin (CCK) and peptide YY (PYY) concentrations and energy intake by intraduodenal lauric acid, a fatty acid with 12 carbon atoms ('C12') would be load, but not concentration, dependent.

Who Took Part

PubMed indexes the participants as adults, men only.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

Because people in this Peptide YY study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Peptide YY study, the assignments were hidden from both participants and investigators until the end.

Antropyloroduodenal pressure waves, plasma CCK and PYY, and appetite perceptions were measured during intraduodenal infusions of C12 at (1) different loads of (i) 0.2, (ii) 0.3 and (iii) 0.4 kcal min(-1) (all 56 mM) for 90 min, and (2) different concentrations of (i) 40, (ii) 56 and (iii) 72 mM (all 0.4 kcal min(-1)) for 60 min.

What Was Measured

The subject headings attached to it are Appetite, Cholecystokinin, Duodenum, Energy Intake, Gastrointestinal Motility, Infusions, Parenteral and Lauric Acids.

What This Means in Plain Language

The paper is a randomized and double-blind study of Peptide YY and Cholecystokinin (CCK).

The publication is from 2007 (The Journal of physiology), a journal based in England.

More context: the Peptide YY compound page and the Cholecystokinin (CCK) compound page, all human trials.